Dabur Pharma open offer
European health care firm Fresenius Kabi, which acquired 73.3 per cent control of Dabur Pharma last week, today announced a public offer to purchase further 20 per cent stake in the domestic drug firm at a price of Rs 76.50 per equity share in cash.
The deal for control of the company cost the European firm Rs 878.2 crore and the open offer, if fully subscribed, would cost the new owner around Rs 240 crore.
Fresenius Kabi has also entered into an agreement with a third party to secure the participation of 2.4 per cent of Dabur Pharma share capital in the public offer.
The European firm said the acquisition will be entirely debt financed from funds that have already been procured
